|Dr Patrick Smith (PharmD), Chief Scientific Officer, d3 Medicine LLC|
d3 Medicine LLC is a global company that provides the biopharmaceutical industry with unique access to a virtual drug development team of globally recognised industry practice leaders with a passion to drive change in areas of unmet medical need. Dr. Smith has more than 15 years of global drug development experience and is considered an authority in anti-infective and antiviral clinical pharmacology. Dr. Smith has broad appreciation for all aspects of drug development, with particular emphasis on innovative translational and quantitative approaches in early phase development to optimize speed and efficient proof of concept delivery Past appointment includes Head of U.S. Clinical Pharmacology for Roche, member of key infectious diseases corporate governance committees defining disease area and portfolio strategy. He holds a Research Associate Professor appointment at the State University of New York at Buffalo and has more than 80 peer reviewed publications in top tier journals.
|Dr Craig Rayner (PharmD MBA), CEO, d3 Medicine LLC|
d3 Medicine LLC is a global company that provides the biopharmaceutical industry with unique access to a virtual drug development team of globally recognised industry practice leaders with a passion to drive change in areas of unmet medical need. Dr. Rayner has more than 15 years of drug development experience. His past appointments including Leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), and in Business Development/Licensing as Global Due Diligence Director (Roche). He has extensive experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous Due Diligences, active support of negotiations, deal making and integration activities. He holds an Adjunct Associate Professorship in Pharmaceutical Science, and is broadly published in clinical pharmacology and also infectious diseases.
|Dr John Warren, Clinical Scientist, Medicines Assessment Ltd|
John began Medicines Assessment Ltd as a pharmaceutical consultancy in 2011. He advises multiple pharmaceutical companies on their clinical development programs, including non-executive director advice to the biotech and pharma industry. John is currently Executive Editor for British J Clinical Pharmacology and member of the Joint Specialty Committee for Clinical Pharmacology of the Royal College of Physicians London.John previously worked for the UK Medicines Healthcare products Regulatory Agency (MHRA) as an Expert Medical Assessor from 1995-2010 evaluating new drug applications for the UK and Europe across the therapeutic spectrum. He was a member of the European Scientific Advice Working Party from 2003-2010 and the European Pharmacokinetic Subgroup of the Efficacy Working Party from 2007-2008. He contributed to the EU Notes for Guidance on Asthma, COPD, ARDS and Bioequivalence. When appointed to the MHRA in 1995 John took a concomitant five year Honorary Senior Lecturer post in Clinical Pharmacology at St Thomas’ Hospital.John’s previous appointments also include Senior Lecturer at the National Heart and Lung Institute, with Honorary Consultant status at the Brompton, Charing Cross and Chelsea & Westminster Hospitals, 1990-1994. This followed a Senior Registrar post in Clinical Pharmacology at the Royal Postgraduate Medical School from 1986-1990. He was a Member of the Editorial Board of Clinical Pharmacology & Therapeutics and Microvascular Research.He holds triple specialist accreditation in the UK in General Medicine, Clinical Pharmacology and Cardiology and is the author of over 100 publications in international journals on the physiology and pharmacology of the autonomic system and a book on the Endothelium.
John has widespread lecturing experience on a range of topics, including conferences organised by Informa, SMi, EU Association of Pharma Biotechnology, EU Center for Regulatory Affairs Freiburg, EU Generic Alliances’ Network, as well as MSc and BSc students at Oxford, Surrey and Kings College London. For a review of drug development please see “Drug Discovery: Lessons from Evolution” Br J Clinical Pharmacology 2011;71:497-503.
|Dr Masamitsu Iino, Professor, Department of Pharmacology, Graduate School of Medicine, The University of Tokyo.|
Masamitsu also serves as Second Vice President of IUPHAR and Secretary General of the 18th World Congress of Basic and Clinical Pharmacology to be held in Kyoto in July 2018. He has been studying the mechanism of intracellular Ca2+ signaling, which is one of the most important biosignals regulating a vast array of cell functions. He discovered regenerativity of intracellular Ca2+ mobilization and showed that the mechanism is responsible for the generation of diverse spatiotemporal patterns of Ca2+ signals. He is now trying to identify new (patho)physiological cell functions that are regulated by Ca2+ signals in the central nervous system, using new methods based on his previous findings. His recent results clarified new Ca2+-dependent mechanisms in brain injury, which may serve as potential therapeutic targets.Selected publications